Mouse Oral Squamous Cell Carcinoma (OSCC) Cell Lines

Transplantable mouse OSCC cell lines derived from independent carcinogen-induced tumors.


  • MOC1 and MOC22: Indolent growth phenotypes
  • MOC2: Aggressive growth phenotype - ability to form tumors with injection of as few as 10,000 cells

Oral cavity squamous cell carcinoma (OSCC) is a prominent subset of head and neck cancers, which are the 6th most common cancer worldwide. The major risk factor for developing OSCC is carcinogen exposure, which distinguishes this subset of head and neck cancers from those induced by human papillomavirus. Despite advances in detection, surgery, chemotherapy, and radiation, the prognosis for OSCC has remained stable for decades. Furthermore, at the time of diagnosis, approximately two-thirds of OSCC patients have locoregionally advanced disease resulting in increased morbidity and mortality.

From the laboratory of Ravindra Uppaluri, MD, PhD, Washington University in Saint Louis.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
Mouse OSCC Cell Line (MOC1), 1 vial
1 vial In stock
Regular Price:$695.00
On Sale:
Mouse OSCC Cell Line (MOC2), 1 vial
1 vial In stock
Regular Price:$695.00
On Sale:
Mouse OSCC Cell Line (MOC22), 1 vial
1 vial In stock
Regular Price:$695.00
On Sale:

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.


Product Type: Cell Line
Name: Mouse Oral Squamous Cell Carcinoma (OSCC) Cell Lines
Cell Type: Mouse oral cancer
Organism: MOC1 and MOC22 were derived from primary tumors in C57BL/6 WT mice. MOC2 was derived from a chemokine receptor CXCR3 deficient mouse on a pure C57BL/6 background (of note, no major differences in the incidence of tumor formation were noted between the different genotypes).
Source: Oral cavity
Biosafety Level: 2
Growth Conditions: PDF Suggested Protocol Kerafast also recommends following cell culture dishes/flasks manufacturer's instructions on cell seeding volume.
Cryopreservation: 10% DMSO
Storage: LN2
Shipped: Dry Ice

From the laboratory of Ravindra Uppaluri, MD, PhD, Washington University in Saint Louis.
  1. Judd NP, Allen CT, Winkler AE, Uppaluri R. Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol Head Neck Surg. 2012 Sep;147(3):493-500. doi: 10.1177/0194599812442037. Epub 2012 Mar 19. PubMed PMID: 22434099; PubMed Central PMCID: PMC6346425.
  2. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012 Jan 1;72(1):365-74. doi: 10.1158/0008-5472.CAN-11-1831. Epub 2011 Nov 15. PubMed PMID: 22086849; PubMed Central PMCID: PMC3286642.
  3. Onken MD, Winkler AE, Kanchi KL, Chalivendra V, Law JH, Rickert CG, Kallogjeri D, Judd NP, Dunn GP, Piccirillo JF, Lewis JS Jr, Mardis ER, Uppaluri R. A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res. 2014 Jun 1;20(11):2873-84. doi: 10.1158/1078-0432.CCR-14-0205. Epub 2014 Mar 25. PubMed PMID: 24668645; PubMed Central PMCID: PMC4096804.
  4. Robbins Y, Greene S, Friedman J, et al. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. Elife. 2020;9:e54854. Published 2020 Jul 7. View article
  5. Anderson K, Ryan N, Alkhimovitch A, Siddiqui A, Oghumu S. Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity. Cancers (Basel). 2021 Feb 25;13(5):953. View article
  6. Kono M, Saito S, Egloff AM, Allen CT, Uppaluri R. The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations. Oral Oncol. 2022 Jul 9;132:106012. doi: 10.1016/j.oraloncology.2022.106012. Epub ahead of print. PMID: 35820346.

If you publish research with this product, please let us know so we can cite your paper.